1
|
Fernández-Mariño I, Anfray C, Crecente-Campo J, Maeda A, Ummarino A, Teijeiro-Valiño C, Blanco-Martinez D, Mpambani F, Poul L, Devalliere J, Germain M, Correa J, Fernandez-Villamarin M, Allavena P, Fernandez-Megia E, Alonso MJ, Andón FT. Mannose-modified hyaluronic acid nanocapsules for the targeting of tumor-associated macrophages. Drug Deliv Transl Res 2023; 13:1896-1911. [PMID: 36472784 PMCID: PMC10238357 DOI: 10.1007/s13346-022-01265-9] [Citation(s) in RCA: 6] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 11/16/2022] [Indexed: 12/12/2022]
Abstract
Tumor-associated macrophages (TAMs), a class of immune cells that play a key role in tumor immunosuppression, are recognized as important targets to improve cancer prognosis and treatment. Consequently, the engineering of drug delivery nanocarriers that can reach TAMs has acquired special relevance. This work describes the development and biological evaluation of a panel of hyaluronic acid (HA) nanocapsules (NCs), with different compositions and prepared by different techniques, designed to target macrophages. The results showed that plain HA NCs did not significantly influence the polarization of M0 and M2-like macrophages towards an M1-like pro-inflammatory phenotype; however, the chemical functionalization of HA with mannose (HA-Man) led to a significant increase of NCs uptake by M2 macrophages in vitro and to an improved biodistribution in a MN/MNCA1 fibrosarcoma mouse model with high infiltration of TAMs. These functionalized HA-Man NCs showed a higher accumulation in the tumor compared to non-modified HA NCs. Finally, the pre-administration of the liposomal liver occupying agent Nanoprimer™ further increased the accumulation of the HA-Man NCs in the tumor. This work highlights the promise shown by the HA-Man NCs to target TAMs and thus provides new options for the development of nanomedicine and immunotherapy-based cancer treatments.
Collapse
Affiliation(s)
- Iago Fernández-Mariño
- Center for Research in Molecular Medicine and Chronic Diseases (CiMUS), Campus Vida, Universidade de Santiago de Compostela, Santiago de Compostela, 15782, Spain
- Department of Pharmacology, Pharmacy and Pharmaceutical Technology, Campus Vida, Universidade de Santiago de Compostela, Santiago de Compostela, 15782, Spain
- Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, 15706, Spain
| | - Clément Anfray
- Laboratory of Cellular Immunology, IRCCS Humanitas Research Hospital, Rozzano-Milan, 20072, Italy
| | - Jose Crecente-Campo
- Center for Research in Molecular Medicine and Chronic Diseases (CiMUS), Campus Vida, Universidade de Santiago de Compostela, Santiago de Compostela, 15782, Spain
- Department of Pharmacology, Pharmacy and Pharmaceutical Technology, Campus Vida, Universidade de Santiago de Compostela, Santiago de Compostela, 15782, Spain
- Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, 15706, Spain
| | - Akihiro Maeda
- Laboratory of Cellular Immunology, IRCCS Humanitas Research Hospital, Rozzano-Milan, 20072, Italy
| | - Aldo Ummarino
- Laboratory of Cellular Immunology, IRCCS Humanitas Research Hospital, Rozzano-Milan, 20072, Italy
| | - Carmen Teijeiro-Valiño
- Nanomag Laboratory, Applied Physics Department, Campus Vida, Universidade de Santiago de Compostela, Santiago de Compostela, 15782, Spain
| | - Dario Blanco-Martinez
- Center for Research in Molecular Medicine and Chronic Diseases (CiMUS), Campus Vida, Universidade de Santiago de Compostela, Santiago de Compostela, 15782, Spain
- Department of Pharmacology, Pharmacy and Pharmaceutical Technology, Campus Vida, Universidade de Santiago de Compostela, Santiago de Compostela, 15782, Spain
- Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, 15706, Spain
| | | | - Laurence Poul
- , Curadigm 60 rue de Wattignies, Paris, 75012, France
| | | | | | - Juan Correa
- Departamento de Química Orgánica, Centro Singular de Investigación en Química Biolóxica e Materiais Moleculares (CIQUS), Universidade de Santiago de Compostela, Jenaro de la Fuente s/n, Santiago de Compostela, 15782, Spain
| | - Marcos Fernandez-Villamarin
- Departamento de Química Orgánica, Centro Singular de Investigación en Química Biolóxica e Materiais Moleculares (CIQUS), Universidade de Santiago de Compostela, Jenaro de la Fuente s/n, Santiago de Compostela, 15782, Spain
| | - Paola Allavena
- Laboratory of Cellular Immunology, IRCCS Humanitas Research Hospital, Rozzano-Milan, 20072, Italy
| | - Eduardo Fernandez-Megia
- Departamento de Química Orgánica, Centro Singular de Investigación en Química Biolóxica e Materiais Moleculares (CIQUS), Universidade de Santiago de Compostela, Jenaro de la Fuente s/n, Santiago de Compostela, 15782, Spain
| | - María José Alonso
- Center for Research in Molecular Medicine and Chronic Diseases (CiMUS), Campus Vida, Universidade de Santiago de Compostela, Santiago de Compostela, 15782, Spain
- Department of Pharmacology, Pharmacy and Pharmaceutical Technology, Campus Vida, Universidade de Santiago de Compostela, Santiago de Compostela, 15782, Spain
- Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, 15706, Spain
| | - Fernando Torres Andón
- Center for Research in Molecular Medicine and Chronic Diseases (CiMUS), Campus Vida, Universidade de Santiago de Compostela, Santiago de Compostela, 15782, Spain.
- Laboratory of Cellular Immunology, IRCCS Humanitas Research Hospital, Rozzano-Milan, 20072, Italy.
| |
Collapse
|
2
|
Saunders NRM, Paolini MS, Fenton OS, Poul L, Devalliere J, Mpambani F, Darmon A, Bergère M, Jibault O, Germain M, Langer R. A Nanoprimer To Improve the Systemic Delivery of siRNA and mRNA. Nano Lett 2020; 20:4264-4269. [PMID: 32357299 DOI: 10.1021/acs.nanolett.0c00752] [Citation(s) in RCA: 46] [Impact Index Per Article: 11.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/11/2023]
Abstract
Despite tremendous interest in gene therapies, the systemic delivery of nucleic acids still faces substantial challenges. To successfully administer nucleic acids, one approach is to encapsulate them in lipid nanoparticles (LNPs). However, LNPs administered intravenously substantially accumulate in the liver where they are taken up by the reticuloendothelial system (RES). Here, we administer prior to the LNPs a liposome designed to transiently occupy liver cells, the Nanoprimer. This study demonstrates that the pretreatment of mice with the Nanoprimer decreases the LNPs' uptake by the RES. By accumulating rapidly in the liver cells, the Nanoprimer improves the bioavailability of the LNPs encapsulating human erythropoietin (hEPO) mRNA or factor VII (FVII) siRNA, leading respectively to more hEPO production (by 32%) or FVII silencing (by 49%). The use of the Nanoprimer offers a new strategy to improve the systemic delivery of RNA-based therapeutics.
Collapse
Affiliation(s)
- Nell R M Saunders
- Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts 02142, United States
| | - Marion S Paolini
- Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts 02142, United States
| | - Owen S Fenton
- Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts 02142, United States
| | | | | | | | | | | | | | | | - Robert Langer
- Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts 02142, United States
- Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts 02142, United States
- Institute for Medical Engineering and Science, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States
- Harvard and MIT Division of Health Science and Technology, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States
| |
Collapse
|